More articles from Volume 48, Issue 1, 2019
Clinical-morphological characteristics of pathological changes in the prostate
Serum Vitamin D analysis in acute viral bronchiolitis
Extracranial carotid atherosclerosis in genesis infarction brain in the border zones supratentorial localization
Oxidative stress parameters in patients with Meniere disease
The impact of occupational stress on work ability of electricians
Specific pattern of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of Alzheimer disease: Case report
,
Branislava Radović
,
L. Brajkovic
S. Nikolic
Abstract
References
1.
Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer’s Disease, and Other Dementias. Vol. 49, Journal of Nuclear Medicine. 2008. p. 390–8.
2.
Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS. Fluorodeoxyglucose-Positron Emission Tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. Vol. 9, BMC Neurology. 2009.
3.
Ishii K. PET Approaches for Diagnosis of Dementia. Vol. 35, American Journal of Neuroradiology. 2014. p. 2030–8.
4.
Perani D, Cerami C, Caminiti SP, Santangelo R, Coppi E, Ferrari L, et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Vol. 43, European Journal of Nuclear Medicine and Molecular Imaging. 2016. p. 499–508.
5.
Herholz K. FDG PET and Differential Diagnosis of Dementia. Vol. 9, Alzheimer Disease & Associated Disorders. 1995. p. 6–16.
6.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Vol. 42, European Journal of Nuclear Medicine and Molecular Imaging. 2015. p. 328–54.
7.
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Vol. 36, European Journal of Nuclear Medicine and Molecular Imaging. 2009. p. 2103–10.
8.
Asenbaum S. Guideline for the use of FDG PET in Neurology and Psychiatry. 2001.
9.
Kuwert T, Bartenstein P, Grünwald F. Clinical value of positron emission tomography in neuromedicine. Vol. 69. 1989. p. 1045–160.
10.
Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Vol. 22, Seminars in Nuclear Medicine. 1992. p. 233–46.
11.
Coleman RE. Positron Emission Tomography Diagnosis of Alzheimer’s Disease. Vol. 2, PET Clinics. 2007. p. 25–34.
12.
Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of Brain Glucose Metabolism in Mild Cognitive Impairment and Clinical Progression to Alzheimer Disease. Vol. 62, Archives of Neurology. 2005. p. 1728.
13.
Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Vol. 6, NeuroImage: Clinical. 2014. p. 445–54.
14.
YAKUSHEV I, HAMMERS A, FELLGIEBEL A, SCHMIDTMANN I, SCHEURICH A, BUCHHOLZ H, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging☆. Vol. 44, NeuroImage. 2009. p. 43–50.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
